LUM-201 plus Semaglutide combination efficacy and safety evaluated in older obese adults
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
Abstract
A phase 2 study evaluates LUM-201 plus Semaglutide versus Semaglutide plus placebo in older obese adults (60-85 years) with mild functional impairment.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
